Nucleic acids encoding plasma kallikrein binding proteins

1. A nucleic acid(s) encoding an antibody that binds plasma kallikrein, wherein the antibody comprises a heavy chain comprising a heavy chain variable region and a heavy chain constant region and a light chain comprising a light chain variable region and a light chain constant region, and wherein the antibody is selected from the group consisting of:

(i) an antibody comprising a heavy chain variable region comprising a complementary determining region (CDR1) set forth as HYIMM (SEQ ID NO: 166), a CDR2 set forth as GIYSSGGITVYADSVKG (SEQ ID NO: 167), and a CDR3 set forth as RRIGVPRRDEFDI (SEQ ID NO: 1171) or RRTGVPRWDDFDI (SEQ ID NO: 1177); and a light chain variable region comprising a CDR1 set forth as RASQSISSWLA (SEQ ID NO: 1172), a CDR2 set forth as KASTLES (SEQ ID NO: 1173), and a CDR3 set forth as QQYNTYWT (SEQ ID NO: 1174);

(ii) an antibody comprising a heavy chain variable region comprising a CDR1 set forth as HYIMM (SEQ ID NO: 166), a CDR2 set forth as GIYSSGGITVYADSVKG (SEQ ID NO: 167), and a CDR3 set forth as RRTGIPRRDAFDI (SEQ ID NO: 1183); and a light chain variable region comprising a CDR1 set forth as RASQSISSWLA (SEQ ID NO: 1172), a CDR2 set forth as KASTLES (SEQ ID NO: 1173), and a CDR3 set forth as QQYNTYWT (SEQ ID NO: 1174);

(iii) an antibody comprising a heavy chain variable region comprising a CDR1 set forth as HYLMT (SEQ ID NO: 1807), a CDR2 set forth as YISPSGGHTIYADSVKG (SEQ ID NO: 1814), and a CDR3 set forth as VARGIAARSRTSYFDY (SEQ ID NO: 1821); and a light chain variable region comprising a CDR1 set forth as RTSQFVNSNYLA (SEQ ID NO: 1822), a CDR2 set forth as GASSRAT (SEQ ID NO: 1823), and a CDR3 set forth as QQSSRTPWT (SEQ ID NO: 1824);

(iv) an antibody comprising a heavy chain variable region comprising a CDR1 set forth as HYLMT (SEQ ID NO: 1807), a CDR2 set forth as YISPSGGHTIYADSVKG (SEQ ID NO: 1814), and a CDR3 set forth as VARGIAARSRTSYFDY (SEQ ID NO: 1821); and a light chain variable region comprising a CDR1 set forth as RTSQFVNSNYLA (SEQ ID NO: 1822), a CDR2 set forth as GASSRAT (SEQ ID NO: 1823), and a CDR3 set forth as QQSSRTPWT (SEQ ID NO: 1824);

(v) an antibody comprising a heavy chain variable region comprising a CDR1 set forth as HYLMT (SEQ ID NO: 1807), a CDR2 set forth as YISPSGGHTIYADSVKG (SEQ ID NO: 1814), and a CDR3 set forth as VARGIAARSRTSYFDY (SEQ ID NO: 1821); and a light chain variable region comprising a CDR1 set forth as RTSQFVNSNYLA (SEQ ID NO: 1822), a CDR2 set forth as GASSRAT (SEQ ID NO: 1823), and a CDR3 set forth as QQSSRTPWT (SEQ ID NO: 1824);

(vi) an antibody comprising a heavy chain variable region comprising a CDR1 set forth as HYLMT (SEQ ID NO: 1807), a CDR2 set forth as YISPSGGHTIYADSVKG (SEQ ID NO: 1814), and a CDR3 set forth as VARGIAARSRTSYFDY (SEQ ID NO: 1821); and a light chain variable region comprising a CDR1 set forth as RASQGISSYLA (SEQ ID NO: 151), a CDR2 set forth as AASTLQS (SEQ ID NO: 152), and a CDR3 set forth as QQLNSYPLT (SEQ ID NO: 153);

(vii) an antibody comprising a heavy chain variable region comprising a CDR1 set forth as AYSMI (SEQ ID NO: 124), a CDR2 set forth as YIRPSGGRTTYADSVKG (SEQ ID NO: 125), and a CDR3 set forth as GGLLLWFRELKSNYFDY (SEQ ID NO: 126); and a light chain variable region comprising a CDR1 set forth as RASQPIDNYLN (SEQ ID NO: 169), a CDR2 set forth as AASRLQS (SEQ ID NO: 170), and a CDR3 set forth as QQSYTVPYT (SEQ ID NO: 171);

(viii) an antibody comprising a heavy chain variable region comprising a CDR1 set forth as AYSMI (SEQ ID NO: 124), a CDR2 set forth as YIRPSGGRTTYADSVKG (SEQ ID NO: 125), and a CDR3 set forth as GGLLLWNRELKSNYFDY (SEQ ID NO: 192); and a light chain variable region comprising a CDR1 set forth as RASQPIDNYLN (SEQ ID NO: 193), a CDR2 set forth as AASRLQS (SEQ ID NO: 170), and a CDR3 set forth as QQSYTVPYT (SEQ ID NO: 171);

(ix) an antibody comprising a heavy chain variable region comprising a CDR1 set forth as AYSMI (SEQ ID NO: 124), a CDR2 set forth as YIRPSGGRTTYADSVKG (SEQ ID NO: 125), and a CDR3 set forth as GGLLLWARELKSNYFDY (SEQ ID NO: 216); and a light chain variable region comprising a CDR1 set forth as RASQPIDNYLN (SEQ ID NO: 193), a CDR2 set forth as AASRLQS (SEQ ID NO: 170), and a CDR3 set forth as QQSYTVPYT (SEQ ID NO: 171);

(x) an antibody comprising a heavy chain variable region comprising a CDR1 set forth as HYLMT (SEQ ID NO: 154), a CDR2 set forth as YISPSGGHTIYADSVKG (SEQ ID NO: 155), and a CDR3 set forth as VGQGIRGRSRTSYFAQ (SEQ ID NO: 1815); and a light chain variable region comprising a CDR1 set forth as RTSQFVNSNYLA (SEQ ID NO: 1816), a CDR2 set forth as GASSRAT (SEQ ID NO: 1817), and a CDR3 set forth as QQSSRTPWT (SEQ ID NO: 1818);

(xi) an antibody comprising a heavy chain variable region comprising a CDR1 set forth as DYMMA (SEQ ID NO: 1819), a CDR2 set forth as SIVPSGGHTHYADSVKG (SEQ ID NO: 1820), and a CDR3 set forth as VARGIAARSRTSYFDY (SEQ ID NO: 1821); and a light chain variable region comprising a CDR1 set forth as RTSQFVNSNYLA (SEQ ID NO: 1816), a CDR2 set forth as GASSRAT (SEQ ID NO: 1817), and a CDR3 set forth as QQSSRTPWT (SEQ ID NO: 1818);

(xii) an antibody comprising a heavy chain variable region comprising a CDR1 set forth as HYLMT (SEQ ID NO: 154), a CDR2 set forth as YISPSGGHTIYADSVKG (SEQ ID NO: 155), and a CDR3 set forth as VAQGIAARSRTSSVDQ (SEQ ID NO: 1827); and a light chain variable region comprising a CDR1 set forth as RTSQFVNSNYLA (SEQ ID NO: 1816), a CDR2 set forth as GASSRAT (SEQ ID NO: 1817), and a CDR3 set forth as QQSSRTPWT (SEQ ID NO: 1818);

(xiii) an antibody comprising a heavy chain variable region comprising a CDR1 set forth as HYLMT (SEQ ID NO: 154), a CDR2 set forth as YISPSGGHTIYADSVKG (SEQ ID NO: 155), and a CDR3 set forth as VAQGISARSRTSYFDY (SEQ ID NO: 1863); and a light chain variable region comprising a CDR1 set forth as RTSQFVNSNYLA (SEQ ID NO: 1816), a CDR2 set forth as GASSRAT (SEQ ID NO: 1817), and a CDR3 set forth as QQSSRTPWT (SEQ ID NO: 1818);

(xiv) an antibody comprising a heavy chain variable region comprising a CDR1 set forth as HYIMM (SEQ ID NO: 166), a CDR2 set forth as GIYSSGGITVYADSVKG (SEQ ID NO: 167), and a CDR3 set forth as RRIGVPRRDSFDM (SEQ ID NO: 1189); and a light chain variable region comprising a CDR1 set forth as RASQSISSWLA (SEQ ID NO: 1172), a CDR2 set forth as KASTLES (SEQ ID NO: 1173), and a CDR3 set forth as QQYNTYWT (SEQ ID NO: 1174);

(xv) an antibody comprising a heavy chain variable region comprising a CDR1 set forth as IYSMH (SEQ ID NO: 1157), a CDR2 set forth as SIYPSRGMTWYADSVKG (SEQ ID NO: 1158), and a CDR3 set forth as RRTGIPRRDAFDI (SEQ ID NO: 1159); and a light chain variable region comprising a CDR1 set forth as RASQSISSWLA (SEQ ID NO: 1172), a CDR2 set forth as KASTLES (SEQ ID NO: 1173), and a CDR3 set forth as QQYNTYWT (SEQ ID NO: 1174);

(xvi) an antibody comprising a heavy chain variable region comprising a CDR1 set forth as HYIMM (SEQ ID NO: 166), a CDR2 set forth as GIYSSGGITVYADSVKG (SEQ ID NO: 167), and a CDR3 set forth as RRTGVPRRDEFDI (SEQ ID NO: 1201); and a light chain variable region comprising a CDR1 set forth as RASQSISSWLA (SEQ ID NO: 1172), a CDR2 set forth as KASTLES (SEQ ID NO: 1173), and a CDR3 set forth as QQYNTYWT (SEQ ID NO: 1174);

(xvii) an antibody comprising a heavy chain variable region comprising a CDR1 set forth as WYTMV (SEQ ID NO: 52), a CDR2 set forth as YIYPSGGATFYADSVKG (SEQ ID NO: 71), and a CDR3 set forth as GSYDYIWGFYSDH (SEQ ID NO: 72); and a light chain variable region comprising a CDR1 set forth as SGNKLGDKYVA (SEQ ID NO: 2361), a CDR2 set forth as QDTKRPS (SEQ ID NO: 2362), and a CDR3 set forth as QAWDSSIVI (SEQ ID NO: 2363);

(xviii) an antibody comprising a heavy chain variable region comprising a CDR1 set forth as HYRMS (SEQ ID NO: 94), a CDR2 set forth as SIYPSGGRTVYADSVKG (SEQ ID NO: 95), and a CDR3 set forth as DKFEWRLLFRGIGNDAFDI (SEQ ID NO: 96); and a light chain variable region comprising a CDR1 set forth as SGDKLGDKYTS (SEQ ID NO: 91), a CDR2 set forth as QDIKRPS (SEQ ID NO: 92), and a CDR3 set forth as QAWDSPNARV (SEQ ID NO: 93);

(xix) an antibody comprising a heavy chain variable region comprising a CDR1 set forth as FYYMV (SEQ ID NO: 16), a CDR2 set forth as VIYPSGGITVYADSVKG (SEQ ID NO: 17), and a CDR3 set forth as DKWAVMPPYYYYAMDV (SEQ ID NO: 18); and a light chain variable region comprising a CDR1 set forth as RASQSIRNYLN (SEQ ID NO: 13), a CDR2 set forth as AASTLQS (SEQ ID NO: 14), and a CDR3 set forth as QQLSGYPHT (SEQ ID NO: 15); and

(xx) an antibody comprising a heavy chain variable region comprising a CDR1 set forth as YYHMS (SEQ ID NO: 82), a CDR2 set forth as VISPSGGSTKYADSVKG (SEQ ID NO: 83), and a CDR3 set forth as GGSSDYAWGSYRRPYYFDY (SEQ ID NO: 84); and a light chain variable region comprising a CDR1 set forth as RASQSVSSYLA (SEQ ID NO: 79), a CDR2 set forth as DASNRAT (SEQ ID NO: 80), and a CDR3 set forth as QQRSNWPRGFT (SEQ ID NO: 81).

2. The nucleic acid(s) of claim 1 , wherein:

(i) the heavy chain variable region of the antibody comprises the amino acid sequence of EVQLLESGGGLVQPGGSLRLSCAASGFTFSHYIMMWVRQAPGKGLEWVSGIYSSGGITVYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAYRRIGVPRRDEFDIWGQGTM VTVSS (SEQ ID NO: 1743) or EVQLLESGGGLVQPGGSLRLSCAASGFTFSHYIMMWVRQAPGKGLEWVSGIYSSGGITV YADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAFRRTGVPRWDDFDIWGQGT MVTVSSASTKGPSVFPLAPSSKS (SEQ ID NO: 1801), and the light chain variable region of the antibody comprises the amino acid sequence of DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASTLESGVPS RFSGSGSGTEFTLTISSLQPDDFATYYCQQYNTYWTFGQGTKVEIK (SEQ ID NO: 2389);

(ii) the heavy chain variable region of the antibody comprises the amino acid sequence of EVQLLESGGGLVQPGGSLRLSCAASGFTFSHYIMMWVRQAPGKGLEWVSGIYSSGGITV YADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAYRRTGIPRRDAFDIWGQGTM VTVSSASTKGPSVFPLAPSSKS (SEQ ID NO: 280) and the light chain variable region of the antibody comprises the amino acid sequence of QDIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPNLLIYKASTLESGVP SRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNTYWTFGQGTKVEIK (SEQ ID NO: 279);

(iii) the heavy chain variable region of the antibody comprises the amino acid sequence of EVQLLESGGGLVQPGGSLRLSCAASGFTFSHYLMTWVRQAPGKGLEWVSYISPSGGHTI YADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARVARGIAARSRTSYFDYWGQ GTLVTVSS (SEQ ID NO: 2564) and the light chain variable region of the antibody comprises the amino acid sequence of EIVLTQSPGTLSLSPGERATLSCRTSQFVNSNYLAWYQQKPGQAPRLLIYGASSRATGIPD RFSGSGSGTDFTLTISRLEPEDFAVYYCQQSSRTPWTFGQGTKVEIK (SEQ ID NO: 2397);

(iv) the heavy chain variable region of the antibody comprises the amino acid sequence of EVQLLESGGGLVQPGGSLRLSCAASGFTFSHYLMTWVRQAPGKGLEWVSYISPSGGHTI YADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARVARGIAARSRTSYFDYWGQ GTLVTVSSASTKGPSVFPLAPSSKS (SEQ ID NO: 1139) and the light chain variable region of the antibody comprises the amino acid sequence of QDIQMTQSPGTLSLSPGERATLSCRTSQFVNSNYLAWYQQTPGQAPRLLIYGASSRATGI PDRFSGTGYGTDFTLTISRLEPEDYGTYYCQQSSRTPWTFGQGTRVEIK (SEQ ID NO: 2560);

(v) the heavy chain variable region of the antibody comprises the amino acid sequence of EVQLLESGGGLVQPGGSLRLSCAASGFTFSHYLMTWVRQAPGKGLEWVSYISPSGGHTI YADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARVARGIAARSRTSYFDYWGQ GTLVTVSS (SEQ ID NO: 2564) and the light chain variable region of the antibody comprises the amino acid sequence of EIVLTQSPGTLSLSPGERATLSCRTSQFVNSNYLAWYQQKPGQAPRLLIYGASSRATGIPD RFSGSGSGTDFTLTISRLEPEDFAVYYCQQSSRTPWTFGQGTKVEIK (SEQ ID NO: 2397);

(vi) the heavy chain variable region of the antibody comprises the amino acid sequence of EVQLLESGGGLVQPGGSLRLSCAASGFTFSHYLMTWVRQAPGKGLEWVSYISPSGGHTI YADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARVARGIAARSRTSYFDYWGQ GTLVTVSSASTKGPSVFPLAPSSKS (SEQ ID NO: 1139) and the light chain variable region of the antibody comprises the amino acid sequence of QDIQMTQSPSFLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVP SRFSGSGSGTEFTLTISSLQPEDFATYYCQQLNSYPLTFGGGTKVEIK (SEQ ID NO: 275);

(vii) the heavy chain variable region of the antibody comprises the amino acid sequence of EVQLLESGGGLVQPGGSLRLSCAASGFTFSAYSMIWVRQAPGKGLEWVSYIRPSGGRTT YADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGGLLLWFRELKSNYFDYW GQGTLVTVSSASTKGPSVFPLAPSSKS (SEQ ID NO: 266) and the light chain variable region of the antibody comprises the amino acid sequence of QDIQMTQSPSSLSAFVGDRVTITCRASQPIDNYLNWYHQKPGKAPKLLIYAASRLQSGVP SRLSGSGFGTDFTLTISSLQPEDFGNYYCQQSYTVPYTFGGGTKVEIR (SEQ ID NO: 265);

(viii) the heavy chain variable region of the antibody comprises the amino acid sequence of EVQLLESGGGLVQPGGSLRLSCAASGFTFSAYSMIWVRQAPGKGLEWVSYIRPSGGRTT YADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGGLLLWNRELKSNYFDYW GQGTLVTVSSASTKGPSVFPLAPSSKS (SEQ ID NO: 288) and the light chain variable region of the antibody comprises the amino acid sequence of QDIQMTQSPSSLSAFVGDRVTITCRASQPIDNYLNWYHQKPGKAPKLLIYAASRLQSGVP SRLSGSGFGTDFTLTISSLQPEDFGNYYCQQSYTVPYTFGGGTKVEIR (SEQ ID NO: 289);

(ix) the heavy chain variable region of the antibody comprises the amino acid sequence of EVQLLESGGGLVQPGGSLRLSCAASGFTFSAYSMIWVRQAPGKGLEWVSYIRPSGGRTT YADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGGLLLWARELKSNYFDYW GQGTLVTVSSASTKGPSVFPLAPSSKS (SEQ ID NO: 296) and the light chain variable region of the antibody comprises the amino acid sequence of QDIQMTQSPSSLSAFVGDRVTITCRASQPIDNYLNWYHQKPGKAPKLLIYAASRLQSGVP SRLSGSGFGTDFTLTISSLQPEDFGNYYCQQSYTVPYTFGGGTKVEIR (SEQ ID NO: 298);

(x) the heavy chain variable region of the antibody comprises the amino acid sequence of EVQLLESGGGLVQPGGSLRLSCAASGFTFSHYLMTWVRQAPGKGLEWVSYISPSGGHTI YADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAMVGQGIRGRSRTSYFAQWG QGTLVTVSS (SEQ ID NO: 2405) and the light chain variable region of the antibody comprises the amino acid sequence of EIVLTQSPGTLSLSPGERATLSCRTSQFVNSNYLAWYQQKPGQAPRLLIYGASSRATGIPD RFSGSGSGTDFTLTISRLEPEDFAVYYCQQSSRTPWTFGQGTKVEIK (SEQ ID NO: 2397);

(xi) the heavy chain variable region of the antibody comprises the amino acid sequence of EVQLLESGGGLVQPGGSLRLSCAASGFTFSDYMMAWVRQAPGKGLEWVSSIVPSGGHT HYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARVARGIAARSRTSYFDYWG QGTLVTVSS (SEQ ID NO: 2407) and the light chain variable region of the antibody comprises the amino acid sequence of EIVLTQSPGTLSLSPGERATLSCRTSQFVNSNYLAWYQQKPGQAPRLLIYGASSRATGIPD RFSGSGSGTDFTLTISRLEPEDFAVYYCQQSSRTPWTFGQGTKVEIK (SEQ ID NO: 2397);

(xii) the heavy chain variable region of the antibody comprises the amino acid sequence of EVQLLESGGGLVQPGGSLRLSCAASGFTFSHYLMTWVRQAPGKGLEWVSYISPSGGHTI YADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARVAQGIAARSRTSSVDQWGQ GTLVTVSS (SEQ ID NO: 2408) and the light chain variable region of the antibody comprises the amino acid sequence of EIVLTQSPGTLSLSPGERATLSCRTSQFVNSNYLAWYQQKPGQAPRLLIYGASSRATGIPD RFSGSGSGTDFTLTISRLEPEDFAVYYCQQSSRTPWTFGQGTKVEIK (SEQ ID NO: 2397);

(xiii) the heavy chain variable region of the antibody comprises the amino acid sequence of EVQLLESGGGLVQPGGSLRLSCAASGFTFSHYLMTWVRQAPGKGLEWVSYISPSGGHTI YADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARVAQGISARSRTSYFDYWGQ GTLVTVSS (SEQ ID NO: 2412) and the light chain variable region of the antibody comprises the amino acid sequence of EIVLTQSPGTLSLSPGERATLSCRTSQFVNSNYLAWYQQKPGQAPRLLIYGASSRATGIPD RFSGSGSGTDFTLTISRLEPEDFAVYYCQQSSRTPWTFGQGTKVEIK (SEQ ID NO: 2397);

(xiv) the heavy chain variable region of the antibody comprises the amino acid sequence of EVQLLESGGGLVQPGGSLRLSCAASGFTFSHYIMMWVRQAPGKGLEWVSGIYSSGGITV YADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAWRRIGVPRRDSFDMWGQGT MVTVSS (SEQ ID NO: 2404) and the light chain variable region of the antibody comprises the amino acid sequence of DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASTLESGVPS RFSGSGSGTEFTLTISSLQPDDFATYYCQQYNTYWTFGQGTKVEIK (SEQ ID NO: 2389);

(xv) the heavy chain variable region of the antibody comprises the amino acid sequence of EVQLLESGGGLVQPGGSLRLSCAASGFTFSIYSMHWVRQAPGKGLEWVSSIYPSRGMT WYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAYRRTGIPRRDAFDIWGQGT MVTVSS (SEQ ID NO: 2406) and the light chain variable region of the antibody comprises the amino acid sequence of DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASTLESGVPS RFSGSGSGTEFTLTISSLQPDDFATYYCQQYNTYWTFGQGTKVEIK (SEQ ID NO: 2389);

(xvi) the heavy chain variable region of the antibody comprises the amino acid sequence of EVQLLESGGGLVQPGGSLRLSCAASGFTFSHYIMMWVRQAPGKGLEWVSGIYSSGGITV YADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAYRRTGVPRRDEFDIWGQGTM VTVSS (SEQ ID NO: 2411) and the light chain variable region of the antibody comprises the amino acid sequence of DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASTLESGVPS RFSGSGSGTEFTLTISSLQPDDFATYYCQQYNTYWTFGQGTKVEIK (SEQ ID NO: 2389);

(xvii) the heavy chain variable region of the antibody comprises the amino acid sequence of EVQLLESGGGLVQPGGSLRLSCAASGFTFSWYTMVWVRQAPGKGLEWVSYIYPSGGAT FYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAMGSYDYIWGFYSDHWGQG TLVTVSSASTKGPSVFPLAPSSKS (SEQ ID NO: 248) and the light chain variable region of the antibody comprises the amino acid sequence of QSALTQPPTVSVSPGQTARITCSGNKLGDKYVAWYQQKPGQSPMLVIYQDTKRPSRVSE RFSGSNSANTATLSISGTQALDEADYYCQAWDSSIVIFGGGTRLTVL (SEQ ID NO: 247);

(xviii) the heavy chain variable region of the antibody comprises the amino acid sequence of EVQLLESGGGLVQPGGSLRLSCAASGFTFSHYRMSWVRQAPGKGLEWVSSIYPSGGRT VYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDKFEWRLLFRGIGNDAFD IWGQGTMVTVSSASTKGPSVFPLAPSSKS (SEQ ID NO: 256) and the light chain variable region of the antibody comprises the amino acid sequence of QSVLTQPPSVSVSPGQTASITCSGDKLGDKYTSWYQQRPGQSPVLVIYQDIKRPSGIPERF SGSNSGNTATLTISGTQAMDEADYYCQAWDSPNARVFGSGTKVTVL (SEQ ID NO: 255);

(xix) the heavy chain variable region of the antibody comprises the amino acid sequence of EVQLLESGGGLVQPGGSLRLSCAASGFTFSFYYMVWVRQAPGKGLEWVSVIYPSGGITV YADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDKWAVMPPYYYYAMDVW GQGTTVTVSS (SEQ ID NO: 2413) and the light chain variable region of the antibody comprises the amino acid sequence of DIQMTQSPSSLSASVGDRVTITCRASQSIRNYLNWYQQKPGKAPNLLIYAASTLQSGVPA RFSGSGSGTDFTLTISSLQPEDFATYYCQQLSGYPHTFGQGTKLEIK (SEQ ID NO: 2398); or

(xx) the heavy chain variable region of the antibody comprises the amino acid sequence of EVQLLESGGGLVQPGGSLRLSCAASGFTFSYYHMSWVRQAPGKGLEWVSVISPSGGSTK YADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGGSSDYAWGSYRRPYYFD YWGQGTLVTVSS (SEQ ID NO: 2414) and the light chain variable region of the antibody comprises the amino acid sequence of QDIQMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIP ARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPRGFTFGPGTKVDIK (SEQ ID NO: 2399).

3. The nucleic acid(s) of claim 1 , wherein the antibody comprises a heavy chain variable region comprising a complementary determining region (CDR1) set forth as HYIMM (SEQ ID NO: 166), a CDR2 set forth as GIYSSGGITVYADSVKG (SEQ ID NO: 167), and a CDR3 set forth as RRIGVPRRDEFDI (SEQ ID NO: 1171) or RRTGVPRWDDFDI (SEQ ID NO: 1177); and a light chain variable region comprising a CDR1 set forth as RASQSISSWLA (SEQ ID NO: 1172), a CDR2 set forth as KASTLES (SEQ ID NO: 1173), and a CDR3 set forth as QQYNTYWT (SEQ ID NO: 1174).

4. The nucleic acid(s) of claim 2 , wherein the heavy chain variable region of the antibody comprises the amino acid sequence of EVQLLESGGGLVQPGGSLRLSCAASGFTFSHYIMMWVRQAPGKGLEWVSGIYSSGGITV YADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAYRRIGVPRRDEFDIWGQGTM VTVSS (SEQ ID NO: 1743) or EVQLLESGGGLVQPGGSLRLSCAASGFTFSHYIMMWVRQAPGKGLEWVSGIYSSGGITV YADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAFRRTGVPRWDDFDIWGQGT MVTVSSASTKGPSVFPLAPSSKS (SEQ ID NO: 1801) and the light chain variable region of the antibody comprises the amino acid sequence of DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASTLESGVPS RFSGSGSGTEFTLTISSLQPDDFATYYCQQYNTYWTFGQGTKVEIK (SEQ ID NO: 2389).

5. The nucleic acid(s) of claim 1 , wherein the antibody is a full-length antibody.

6. The nucleic acid(s) of claim 1 , wherein the antibody is a soluble Fab (sFab).

7. The nucleic acid(s) of claim 5 , wherein the antibody is an IgG.

8. A vector(s) comprising the nucleic acid(s) of claim 1 .

9. The vector(s) of claim 8 , wherein the vector(s) is an expression vector(s).

10. A host cell comprising the nucleic acid(s) of claim 1 .

11. The host cell of claim 10 , wherein the cell is a mammalian cell.

12. The host cell of claim 11 , wherein the mammalian cell is a Chinese Hamster Ovarian (CHO) cell.

13. A host cell comprising the vector(s) of claim 8 .

14. The host cell of claim 13 , wherein the cell is a mammalian cell.

15. The host cell of claim 14 , wherein the mammalian cell is a Chinese Hamster Ovarian (CHO) cell.

16. A method of producing an antibody comprising culturing the host cell of claim 10 in a culture medium, thereby producing the antibody.

17. The method of claim 16 , further comprising purifying the antibody.

18. A method of producing an antibody comprising culturing the host cell of claim 13 in a culture medium, thereby producing the antibody.

19. The method of claim 18 , further comprising recovering the antibody from the culture medium.

20. The method of claim 19 , further comprising purifying the antibody.

21. The method of claim 16 , further comprising recovering the antibody from the culture medium.